• Sprint Bioscience will present new preclinical data from its VRK1 cancer program at ENA 2026 in Barcelona on Nov. 18-20, 2026.
• The poster reports that selective VRK1 inhibition reduced glioblastoma growth in lab and animal studies, supporting the target’s therapeutic rationale.
• Findings build on previously reported results, adding support for VRK1 as a potential approach for genetically defined cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sprint Bioscience AB published the original content used to generate this news brief on October 12, 2026, and is solely responsible for the information contained therein.